Mind Medicine (MindMed) Inc
MNMD9.300USD
+0.860+10.19%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
704.97MCap. mercado
PérdidaP/E TTM
Más Datos de Mind Medicine (MindMed) Inc Compañía
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Información de la empresa
Símbolo de cotizaciónMNMD
Nombre de la empresaMind Medicine (MindMed) Inc
Fecha de salida a bolsaMay 04, 2015
Director ejecutivoMr. Robert (Rob) Barrow
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
DirecciónOne World Trade Center
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10007
Teléfono12122206633
Sitio Web
Símbolo de cotizaciónMNMD
Fecha de salida a bolsaMay 04, 2015
Director ejecutivoMr. Robert (Rob) Barrow
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
250.05K
-9.58%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
42.63K
-21.23%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Brandi L. Roberts
Ms. Brandi L. Roberts
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
250.05K
-9.58%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
42.63K
-21.23%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Brandi L. Roberts
Ms. Brandi L. Roberts
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
6.84%
Commodore Capital LP
5.95%
Blackstone Alternative Asset Management, L.P.
4.71%
Driehaus Capital Management, LLC
4.40%
Octagon Capital Advisors LP
3.97%
Other
74.13%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
6.84%
Commodore Capital LP
5.95%
Blackstone Alternative Asset Management, L.P.
4.71%
Driehaus Capital Management, LLC
4.40%
Octagon Capital Advisors LP
3.97%
Other
74.13%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
21.93%
Hedge Fund
17.33%
Investment Advisor
13.50%
Research Firm
1.70%
Individual Investor
1.09%
Bank and Trust
0.28%
Pension Fund
0.19%
Venture Capital
0.17%
Insurance Company
0.04%
Other
43.76%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
378
42.50M
56.25%
-6.01M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
2023Q1
386
7.15M
19.19%
-755.92K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
5.20M
6.88%
-370.12K
-6.64%
Mar 31, 2025
Commodore Capital LP
4.53M
5.99%
+216.57K
+5.03%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.75%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
3.35M
4.44%
-24.80K
-0.73%
Mar 31, 2025
Octagon Capital Advisors LP
3.02M
3.99%
--
--
Mar 31, 2025
Marshall Wace LLP
2.59M
3.43%
+91.77K
+3.67%
Mar 31, 2025
Deep Track Capital LP
2.50M
3.31%
-316.59K
-11.24%
Mar 31, 2025
State Street Global Advisors (US)
1.84M
2.44%
+60.72K
+3.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.75M
2.32%
-144.28K
-7.60%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.67M
2.21%
-56.30K
-3.27%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
AdvisorShares Psychedelics ETF
8.73%
SPDR S&P Pharmaceuticals ETF
0.85%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.6%
iShares U.S. Pharmaceuticals ETF
0.22%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Nuveen ESG Small-Cap ETF
0.04%
iShares Russell 2000 Value ETF
0.03%
Ver más
AdvisorShares Psychedelics ETF
Proporción8.73%
SPDR S&P Pharmaceuticals ETF
Proporción0.85%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.6%
iShares U.S. Pharmaceuticals ETF
Proporción0.22%
iShares Micro-Cap ETF
Proporción0.11%
ProShares Ultra Nasdaq Biotechnology
Proporción0.05%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
Nuveen ESG Small-Cap ETF
Proporción0.04%
iShares Russell 2000 Value ETF
Proporción0.03%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Fecha
Tipo
Relación
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
